Cytomegalovirus Seropositivity Predicts a Decline in the T Cell But Not the Antibody Response to Influenza in Vaccinated Older Adults Independent of Type 2 Diabetes Status.
Identifieur interne : 000117 ( Main/Exploration ); précédent : 000116; suivant : 000118Cytomegalovirus Seropositivity Predicts a Decline in the T Cell But Not the Antibody Response to Influenza in Vaccinated Older Adults Independent of Type 2 Diabetes Status.
Auteurs : Kamran Haq [Canada] ; Tamas Fulop [Canada] ; Gale Tedder [Canada] ; Beth Gentleman [Canada] ; Hugo Garneau [Canada] ; Graydon S. Meneilly [Canada] ; Alison Kleppinger ; Graham Pawelec [Allemagne, Royaume-Uni] ; Janet E. Mcelhaney [Canada]Source :
- The journals of gerontology. Series A, Biological sciences and medical sciences [ 1758-535X ] ; 2017.
Descripteurs français
- KwdFr :
- Colombie-Britannique (MeSH), Cytokines (sang), Diabète de type 2 (immunologie), Femelle (MeSH), Granzymes (sang), Grippe humaine (immunologie), Grippe humaine (prévention et contrôle), Humains (MeSH), Infections à cytomégalovirus (immunologie), Lymphocytes T (immunologie), Mâle (MeSH), Production d'anticorps (immunologie), Sous-type H3N2 du virus de la grippe A (MeSH), Sujet âgé (MeSH), Test ELISA (MeSH), Tests d'inhibition de l'hémagglutination (MeSH), Vaccins antigrippaux (immunologie), Valeur prédictive des tests (MeSH), Études cas-témoins (MeSH).
- MESH :
- immunologie : Diabète de type 2, Grippe humaine, Infections à cytomégalovirus, Lymphocytes T, Production d'anticorps, Vaccins antigrippaux.
- prévention et contrôle : Grippe humaine.
- sang : Cytokines, Granzymes.
- Colombie-Britannique, Femelle, Humains, Mâle, Sous-type H3N2 du virus de la grippe A, Sujet âgé, Test ELISA, Tests d'inhibition de l'hémagglutination, Valeur prédictive des tests, Études cas-témoins.
English descriptors
- KwdEn :
- Aged (MeSH), Antibody Formation (immunology), British Columbia (MeSH), Case-Control Studies (MeSH), Cytokines (blood), Cytomegalovirus Infections (immunology), Diabetes Mellitus, Type 2 (immunology), Enzyme-Linked Immunosorbent Assay (MeSH), Female (MeSH), Granzymes (blood), Hemagglutination Inhibition Tests (MeSH), Humans (MeSH), Influenza A Virus, H3N2 Subtype (MeSH), Influenza Vaccines (immunology), Influenza, Human (immunology), Influenza, Human (prevention & control), Male (MeSH), Predictive Value of Tests (MeSH), T-Lymphocytes (immunology).
- MESH :
- chemical , blood : Cytokines, Granzymes.
- immunology : Antibody Formation, Cytomegalovirus Infections, Diabetes Mellitus, Type 2, Influenza Vaccines, Influenza, Human, T-Lymphocytes.
- prevention & control : Influenza, Human.
- Aged, British Columbia, Case-Control Studies, Enzyme-Linked Immunosorbent Assay, Female, Hemagglutination Inhibition Tests, Humans, Influenza A Virus, H3N2 Subtype, Male, Predictive Value of Tests.
Abstract
Type 2 diabetes mellitus (T2DM) and persistent cytomegalovirus (CMV) infection are postulated contributors to inflammatory processes that impact on the age-related decline in T-cell responses to influenza vaccination. Older subjects with T2DM (n = 30) and healthy aged controls (n = 40) were enrolled and received influenza vaccination in this study. Serum inflammatory markers and CMV serostatus were measured. Pre- to post-vaccination changes in serum antibody titers to the A/H3N2 strain, and levels of granzyme B (GrB, cytotoxic T lymphocytes) in lysates and cytokines in supernatants from influenza A/H3N2-challenged peripheral blood mononuclear cells were measured. We found no difference between the T2DM and healthy groups in the immune responses measured. However, CMV serostatus was a key determinant of the GrB response to influenza challenge; CMV+ subjects had low levels of inducible GrB (iGrB) activity in response to influenza challenge. In contrast, the serum antibody response to the A/H3N2 vaccine strain did not differ with CMV serostatus, and serum levels of the inflammatory marker, β2-microglobulin, were positively correlated with age, T2DM, and serum IL-10 levels. In conclusion, CMV seropositivity associated with a decline in GrB responses to influenza may predict increased susceptibility to influenza in older adults.
DOI: 10.1093/gerona/glw216
PubMed: 27789617
PubMed Central: PMC5861868
Affiliations:
- Allemagne, Canada, Royaume-Uni
- Bade-Wurtemberg, Colombie-Britannique, District de Tübingen
- Tübingen, Vancouver
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cytomegalovirus Seropositivity Predicts a Decline in the T Cell But Not the Antibody Response to Influenza in Vaccinated Older Adults Independent of Type 2 Diabetes Status.</title><author><name sortKey="Haq, Kamran" sort="Haq, Kamran" uniqKey="Haq K" first="Kamran" last="Haq">Kamran Haq</name><affiliation wicri:level="1"><nlm:affiliation>Health Sciences North Research Institute, Sudbury, ON, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Health Sciences North Research Institute, Sudbury, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation></author><author><name sortKey="Fulop, Tamas" sort="Fulop, Tamas" uniqKey="Fulop T" first="Tamas" last="Fulop">Tamas Fulop</name><affiliation wicri:level="1"><nlm:affiliation>Research Center on Aging, Université de Sherbrooke, Sherbrooke, QC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Research Center on Aging, Université de Sherbrooke, Sherbrooke, QC</wicri:regionArea><wicri:noRegion>QC</wicri:noRegion></affiliation></author><author><name sortKey="Tedder, Gale" sort="Tedder, Gale" uniqKey="Tedder G" first="Gale" last="Tedder">Gale Tedder</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medicine, University of British Columbia, Vancouver, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, University of British Columbia, Vancouver</wicri:regionArea><placeName><settlement type="city">Vancouver</settlement><region type="state">Colombie-Britannique</region></placeName></affiliation></author><author><name sortKey="Gentleman, Beth" sort="Gentleman, Beth" uniqKey="Gentleman B" first="Beth" last="Gentleman">Beth Gentleman</name><affiliation wicri:level="1"><nlm:affiliation>Health Sciences North Research Institute, Sudbury, ON, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Health Sciences North Research Institute, Sudbury, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation></author><author><name sortKey="Garneau, Hugo" sort="Garneau, Hugo" uniqKey="Garneau H" first="Hugo" last="Garneau">Hugo Garneau</name><affiliation wicri:level="1"><nlm:affiliation>Research Center on Aging, Université de Sherbrooke, Sherbrooke, QC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Research Center on Aging, Université de Sherbrooke, Sherbrooke, QC</wicri:regionArea><wicri:noRegion>QC</wicri:noRegion></affiliation></author><author><name sortKey="Meneilly, Graydon S" sort="Meneilly, Graydon S" uniqKey="Meneilly G" first="Graydon S" last="Meneilly">Graydon S. Meneilly</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medicine, University of British Columbia, Vancouver, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, University of British Columbia, Vancouver</wicri:regionArea><placeName><settlement type="city">Vancouver</settlement><region type="state">Colombie-Britannique</region></placeName></affiliation></author><author><name sortKey="Kleppinger, Alison" sort="Kleppinger, Alison" uniqKey="Kleppinger A" first="Alison" last="Kleppinger">Alison Kleppinger</name><affiliation><nlm:affiliation>University of Connecticut Center on Aging, Farmington.</nlm:affiliation><wicri:noCountry code="subField">Farmington</wicri:noCountry></affiliation></author><author><name sortKey="Pawelec, Graham" sort="Pawelec, Graham" uniqKey="Pawelec G" first="Graham" last="Pawelec">Graham Pawelec</name><affiliation wicri:level="3"><nlm:affiliation>Second Department of Internal Medicine, University of Tübingen Medical School, Tübingen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Second Department of Internal Medicine, University of Tübingen Medical School, Tübingen</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Tübingen</region><settlement type="city">Tübingen</settlement></placeName></affiliation><affiliation wicri:level="1"><nlm:affiliation>School of Science and Technology, College of Arts and Science, Nottingham Trent University, Nottingham, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>School of Science and Technology, College of Arts and Science, Nottingham Trent University, Nottingham</wicri:regionArea><wicri:noRegion>Nottingham</wicri:noRegion></affiliation></author><author><name sortKey="Mcelhaney, Janet E" sort="Mcelhaney, Janet E" uniqKey="Mcelhaney J" first="Janet E" last="Mcelhaney">Janet E. Mcelhaney</name><affiliation wicri:level="1"><nlm:affiliation>Health Sciences North Research Institute, Sudbury, ON, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Health Sciences North Research Institute, Sudbury, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation><affiliation><nlm:affiliation>University of Connecticut Center on Aging, Farmington.</nlm:affiliation><wicri:noCountry code="subField">Farmington</wicri:noCountry></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:27789617</idno><idno type="pmid">27789617</idno><idno type="doi">10.1093/gerona/glw216</idno><idno type="pmc">PMC5861868</idno><idno type="wicri:Area/Main/Corpus">000131</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000131</idno><idno type="wicri:Area/Main/Curation">000131</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000131</idno><idno type="wicri:Area/Main/Exploration">000131</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Cytomegalovirus Seropositivity Predicts a Decline in the T Cell But Not the Antibody Response to Influenza in Vaccinated Older Adults Independent of Type 2 Diabetes Status.</title><author><name sortKey="Haq, Kamran" sort="Haq, Kamran" uniqKey="Haq K" first="Kamran" last="Haq">Kamran Haq</name><affiliation wicri:level="1"><nlm:affiliation>Health Sciences North Research Institute, Sudbury, ON, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Health Sciences North Research Institute, Sudbury, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation></author><author><name sortKey="Fulop, Tamas" sort="Fulop, Tamas" uniqKey="Fulop T" first="Tamas" last="Fulop">Tamas Fulop</name><affiliation wicri:level="1"><nlm:affiliation>Research Center on Aging, Université de Sherbrooke, Sherbrooke, QC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Research Center on Aging, Université de Sherbrooke, Sherbrooke, QC</wicri:regionArea><wicri:noRegion>QC</wicri:noRegion></affiliation></author><author><name sortKey="Tedder, Gale" sort="Tedder, Gale" uniqKey="Tedder G" first="Gale" last="Tedder">Gale Tedder</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medicine, University of British Columbia, Vancouver, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, University of British Columbia, Vancouver</wicri:regionArea><placeName><settlement type="city">Vancouver</settlement><region type="state">Colombie-Britannique</region></placeName></affiliation></author><author><name sortKey="Gentleman, Beth" sort="Gentleman, Beth" uniqKey="Gentleman B" first="Beth" last="Gentleman">Beth Gentleman</name><affiliation wicri:level="1"><nlm:affiliation>Health Sciences North Research Institute, Sudbury, ON, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Health Sciences North Research Institute, Sudbury, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation></author><author><name sortKey="Garneau, Hugo" sort="Garneau, Hugo" uniqKey="Garneau H" first="Hugo" last="Garneau">Hugo Garneau</name><affiliation wicri:level="1"><nlm:affiliation>Research Center on Aging, Université de Sherbrooke, Sherbrooke, QC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Research Center on Aging, Université de Sherbrooke, Sherbrooke, QC</wicri:regionArea><wicri:noRegion>QC</wicri:noRegion></affiliation></author><author><name sortKey="Meneilly, Graydon S" sort="Meneilly, Graydon S" uniqKey="Meneilly G" first="Graydon S" last="Meneilly">Graydon S. Meneilly</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medicine, University of British Columbia, Vancouver, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, University of British Columbia, Vancouver</wicri:regionArea><placeName><settlement type="city">Vancouver</settlement><region type="state">Colombie-Britannique</region></placeName></affiliation></author><author><name sortKey="Kleppinger, Alison" sort="Kleppinger, Alison" uniqKey="Kleppinger A" first="Alison" last="Kleppinger">Alison Kleppinger</name><affiliation><nlm:affiliation>University of Connecticut Center on Aging, Farmington.</nlm:affiliation><wicri:noCountry code="subField">Farmington</wicri:noCountry></affiliation></author><author><name sortKey="Pawelec, Graham" sort="Pawelec, Graham" uniqKey="Pawelec G" first="Graham" last="Pawelec">Graham Pawelec</name><affiliation wicri:level="3"><nlm:affiliation>Second Department of Internal Medicine, University of Tübingen Medical School, Tübingen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Second Department of Internal Medicine, University of Tübingen Medical School, Tübingen</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Tübingen</region><settlement type="city">Tübingen</settlement></placeName></affiliation><affiliation wicri:level="1"><nlm:affiliation>School of Science and Technology, College of Arts and Science, Nottingham Trent University, Nottingham, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>School of Science and Technology, College of Arts and Science, Nottingham Trent University, Nottingham</wicri:regionArea><wicri:noRegion>Nottingham</wicri:noRegion></affiliation></author><author><name sortKey="Mcelhaney, Janet E" sort="Mcelhaney, Janet E" uniqKey="Mcelhaney J" first="Janet E" last="Mcelhaney">Janet E. Mcelhaney</name><affiliation wicri:level="1"><nlm:affiliation>Health Sciences North Research Institute, Sudbury, ON, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Health Sciences North Research Institute, Sudbury, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation><affiliation><nlm:affiliation>University of Connecticut Center on Aging, Farmington.</nlm:affiliation><wicri:noCountry code="subField">Farmington</wicri:noCountry></affiliation></author></analytic><series><title level="j">The journals of gerontology. Series A, Biological sciences and medical sciences</title><idno type="eISSN">1758-535X</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged (MeSH)</term><term>Antibody Formation (immunology)</term><term>British Columbia (MeSH)</term><term>Case-Control Studies (MeSH)</term><term>Cytokines (blood)</term><term>Cytomegalovirus Infections (immunology)</term><term>Diabetes Mellitus, Type 2 (immunology)</term><term>Enzyme-Linked Immunosorbent Assay (MeSH)</term><term>Female (MeSH)</term><term>Granzymes (blood)</term><term>Hemagglutination Inhibition Tests (MeSH)</term><term>Humans (MeSH)</term><term>Influenza A Virus, H3N2 Subtype (MeSH)</term><term>Influenza Vaccines (immunology)</term><term>Influenza, Human (immunology)</term><term>Influenza, Human (prevention & control)</term><term>Male (MeSH)</term><term>Predictive Value of Tests (MeSH)</term><term>T-Lymphocytes (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Colombie-Britannique (MeSH)</term><term>Cytokines (sang)</term><term>Diabète de type 2 (immunologie)</term><term>Femelle (MeSH)</term><term>Granzymes (sang)</term><term>Grippe humaine (immunologie)</term><term>Grippe humaine (prévention et contrôle)</term><term>Humains (MeSH)</term><term>Infections à cytomégalovirus (immunologie)</term><term>Lymphocytes T (immunologie)</term><term>Mâle (MeSH)</term><term>Production d'anticorps (immunologie)</term><term>Sous-type H3N2 du virus de la grippe A (MeSH)</term><term>Sujet âgé (MeSH)</term><term>Test ELISA (MeSH)</term><term>Tests d'inhibition de l'hémagglutination (MeSH)</term><term>Vaccins antigrippaux (immunologie)</term><term>Valeur prédictive des tests (MeSH)</term><term>Études cas-témoins (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Cytokines</term><term>Granzymes</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Diabète de type 2</term><term>Grippe humaine</term><term>Infections à cytomégalovirus</term><term>Lymphocytes T</term><term>Production d'anticorps</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Antibody Formation</term><term>Cytomegalovirus Infections</term><term>Diabetes Mellitus, Type 2</term><term>Influenza Vaccines</term><term>Influenza, Human</term><term>T-Lymphocytes</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Cytokines</term><term>Granzymes</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>British Columbia</term><term>Case-Control Studies</term><term>Enzyme-Linked Immunosorbent Assay</term><term>Female</term><term>Hemagglutination Inhibition Tests</term><term>Humans</term><term>Influenza A Virus, H3N2 Subtype</term><term>Male</term><term>Predictive Value of Tests</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Colombie-Britannique</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Sous-type H3N2 du virus de la grippe A</term><term>Sujet âgé</term><term>Test ELISA</term><term>Tests d'inhibition de l'hémagglutination</term><term>Valeur prédictive des tests</term><term>Études cas-témoins</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Type 2 diabetes mellitus (T2DM) and persistent cytomegalovirus (CMV) infection are postulated contributors to inflammatory processes that impact on the age-related decline in T-cell responses to influenza vaccination. Older subjects with T2DM (n = 30) and healthy aged controls (n = 40) were enrolled and received influenza vaccination in this study. Serum inflammatory markers and CMV serostatus were measured. Pre- to post-vaccination changes in serum antibody titers to the A/H3N2 strain, and levels of granzyme B (GrB, cytotoxic T lymphocytes) in lysates and cytokines in supernatants from influenza A/H3N2-challenged peripheral blood mononuclear cells were measured. We found no difference between the T2DM and healthy groups in the immune responses measured. However, CMV serostatus was a key determinant of the GrB response to influenza challenge; CMV+ subjects had low levels of inducible GrB (iGrB) activity in response to influenza challenge. In contrast, the serum antibody response to the A/H3N2 vaccine strain did not differ with CMV serostatus, and serum levels of the inflammatory marker, β2-microglobulin, were positively correlated with age, T2DM, and serum IL-10 levels. In conclusion, CMV seropositivity associated with a decline in GrB responses to influenza may predict increased susceptibility to influenza in older adults.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27789617</PMID><DateCompleted><Year>2017</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1758-535X</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>9</Issue><PubDate><Year>2017</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>The journals of gerontology. Series A, Biological sciences and medical sciences</Title><ISOAbbreviation>J. Gerontol. A Biol. Sci. Med. Sci.</ISOAbbreviation></Journal><ArticleTitle>Cytomegalovirus Seropositivity Predicts a Decline in the T Cell But Not the Antibody Response to Influenza in Vaccinated Older Adults Independent of Type 2 Diabetes Status.</ArticleTitle><Pagination><MedlinePgn>1163-1170</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/gerona/glw216</ELocationID><Abstract><AbstractText>Type 2 diabetes mellitus (T2DM) and persistent cytomegalovirus (CMV) infection are postulated contributors to inflammatory processes that impact on the age-related decline in T-cell responses to influenza vaccination. Older subjects with T2DM (n = 30) and healthy aged controls (n = 40) were enrolled and received influenza vaccination in this study. Serum inflammatory markers and CMV serostatus were measured. Pre- to post-vaccination changes in serum antibody titers to the A/H3N2 strain, and levels of granzyme B (GrB, cytotoxic T lymphocytes) in lysates and cytokines in supernatants from influenza A/H3N2-challenged peripheral blood mononuclear cells were measured. We found no difference between the T2DM and healthy groups in the immune responses measured. However, CMV serostatus was a key determinant of the GrB response to influenza challenge; CMV+ subjects had low levels of inducible GrB (iGrB) activity in response to influenza challenge. In contrast, the serum antibody response to the A/H3N2 vaccine strain did not differ with CMV serostatus, and serum levels of the inflammatory marker, β2-microglobulin, were positively correlated with age, T2DM, and serum IL-10 levels. In conclusion, CMV seropositivity associated with a decline in GrB responses to influenza may predict increased susceptibility to influenza in older adults.</AbstractText><CopyrightInformation>© The Author 2016. Published by Oxford University Press on behalf of The Gerontological Society of America.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Haq</LastName><ForeName>Kamran</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Health Sciences North Research Institute, Sudbury, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fulop</LastName><ForeName>Tamas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Research Center on Aging, Université de Sherbrooke, Sherbrooke, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tedder</LastName><ForeName>Gale</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gentleman</LastName><ForeName>Beth</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Health Sciences North Research Institute, Sudbury, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garneau</LastName><ForeName>Hugo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Research Center on Aging, Université de Sherbrooke, Sherbrooke, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meneilly</LastName><ForeName>Graydon S</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kleppinger</LastName><ForeName>Alison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University of Connecticut Center on Aging, Farmington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pawelec</LastName><ForeName>Graham</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Second Department of Internal Medicine, University of Tübingen Medical School, Tübingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Science and Technology, College of Arts and Science, Nottingham Trent University, Nottingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McElhaney</LastName><ForeName>Janet E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Health Sciences North Research Institute, Sudbury, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Connecticut Center on Aging, Farmington.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Gerontol A Biol Sci Med Sci</MedlineTA><NlmUniqueID>9502837</NlmUniqueID><ISSNLinking>1079-5006</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="D053804">Granzymes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000917" MajorTopicYN="N">Antibody Formation</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001955" MajorTopicYN="N">British Columbia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003586" MajorTopicYN="N">Cytomegalovirus Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053804" MajorTopicYN="N">Granzymes</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006385" MajorTopicYN="N">Hemagglutination Inhibition Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053122" MajorTopicYN="N">Influenza A Virus, H3N2 Subtype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cytomegalovirus (CMV)</Keyword><Keyword MajorTopicYN="N">Granzyme B</Keyword><Keyword MajorTopicYN="N">Influenza vaccination</Keyword><Keyword MajorTopicYN="N">Older adults</Keyword><Keyword MajorTopicYN="N">T cell</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>07</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27789617</ArticleId><ArticleId IdType="pii">glw216</ArticleId><ArticleId IdType="doi">10.1093/gerona/glw216</ArticleId><ArticleId IdType="pmc">PMC5861868</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Gerontol A Biol Sci Med Sci. 2014 Jun;69 Suppl 1:S4-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24833586</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2010 Aug 31;28(38):6145-51</Citation><ArticleIdList><ArticleId IdType="pubmed">20646987</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Gerontol. 2014 Jun;54:1-5</Citation><ArticleIdList><ArticleId IdType="pubmed">24291068</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2010 Aug;84(15):7662-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20484500</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2013 Jun;13(6):485-96</Citation><ArticleIdList><ArticleId IdType="pubmed">23518156</ArticleId></ArticleIdList></Reference><Reference><Citation>Methods Mol Biol. 2015;1343:121-41</Citation><ArticleIdList><ArticleId IdType="pubmed">26420714</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2011 Jun 24;29(29-30):4869-74</Citation><ArticleIdList><ArticleId IdType="pubmed">21497631</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2004 Sep 15;292(11):1333-40</Citation><ArticleIdList><ArticleId IdType="pubmed">15367555</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2010 Apr 26;28(19):3416-22</Citation><ArticleIdList><ArticleId IdType="pubmed">20206285</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Gerontol. 2011 Jun;46(6):489-99</Citation><ArticleIdList><ArticleId IdType="pubmed">21316440</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2007 Jan 8;25(4):599-604</Citation><ArticleIdList><ArticleId IdType="pubmed">17014937</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Transl Med. 2015 Apr 1;7(281):281ra43</Citation><ArticleIdList><ArticleId IdType="pubmed">25834109</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol Methods. 2006 Jan 20;308(1-2):156-66</Citation><ArticleIdList><ArticleId IdType="pubmed">16375915</ArticleId></ArticleIdList></Reference><Reference><Citation>Age (Dordr). 2013 Jun;35(3):563-72</Citation><ArticleIdList><ArticleId IdType="pubmed">22252437</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2005 Jul 8;23 Suppl 1:S10-25</Citation><ArticleIdList><ArticleId IdType="pubmed">15908062</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Intern Med. 2008 Jan 28;168(2):200-6</Citation><ArticleIdList><ArticleId IdType="pubmed">18227369</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gerontol A Biol Sci Med Sci. 2016 May;71(5):610-8</Citation><ArticleIdList><ArticleId IdType="pubmed">26286603</ArticleId></ArticleIdList></Reference><Reference><Citation>Mech Ageing Dev. 2007 May-Jun;128(5-6):392-400</Citation><ArticleIdList><ArticleId IdType="pubmed">17570460</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Death Differ. 2010 Apr;17(4):565-6</Citation><ArticleIdList><ArticleId IdType="pubmed">20228822</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell. 2011 Oct 21;44(2):265-78</Citation><ArticleIdList><ArticleId IdType="pubmed">22017873</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ Open Diabetes Res Care. 2015 Oct 13;3(1):e000140</Citation><ArticleIdList><ArticleId IdType="pubmed">26504526</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Med. 2015 Mar 17;13:53</Citation><ArticleIdList><ArticleId IdType="pubmed">25857236</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2014 Oct 1;193(7):3624-31</Citation><ArticleIdList><ArticleId IdType="pubmed">25187662</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2011 Mar 3;29(11):2169-77</Citation><ArticleIdList><ArticleId IdType="pubmed">21353149</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunol Rev. 2005 Jun;205:257-68</Citation><ArticleIdList><ArticleId IdType="pubmed">15882359</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2009 Apr 21;27(18):2418-25</Citation><ArticleIdList><ArticleId IdType="pubmed">19368783</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2015 Mar 17;33(12):1433-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25659271</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ Open. 2015 Dec 01;5(12):e008737</Citation><ArticleIdList><ArticleId IdType="pubmed">26631055</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2015 Apr 1;211(7):1174-84</Citation><ArticleIdList><ArticleId IdType="pubmed">25367297</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2011 Jan 15;203(2):158-67</Citation><ArticleIdList><ArticleId IdType="pubmed">21288814</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2014 Aug 14;371(7):635-45</Citation><ArticleIdList><ArticleId IdType="pubmed">25119609</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncotarget. 2016 Jun 28;7(26):39171-39183</Citation><ArticleIdList><ArticleId IdType="pubmed">27322555</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2003 Jan 8;289(2):179-86</Citation><ArticleIdList><ArticleId IdType="pubmed">12517228</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2013 Sep;85(9):1557-60</Citation><ArticleIdList><ArticleId IdType="pubmed">23852679</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2012 Mar 9;30(12):2060-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22289511</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Immunol. 2009 Aug;21(4):440-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19535233</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2006 May 15;176(10):6333-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16670345</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li><li>Canada</li><li>Royaume-Uni</li></country><region><li>Bade-Wurtemberg</li><li>Colombie-Britannique</li><li>District de Tübingen</li></region><settlement><li>Tübingen</li><li>Vancouver</li></settlement></list><tree><noCountry><name sortKey="Kleppinger, Alison" sort="Kleppinger, Alison" uniqKey="Kleppinger A" first="Alison" last="Kleppinger">Alison Kleppinger</name></noCountry><country name="Canada"><noRegion><name sortKey="Haq, Kamran" sort="Haq, Kamran" uniqKey="Haq K" first="Kamran" last="Haq">Kamran Haq</name></noRegion><name sortKey="Fulop, Tamas" sort="Fulop, Tamas" uniqKey="Fulop T" first="Tamas" last="Fulop">Tamas Fulop</name><name sortKey="Garneau, Hugo" sort="Garneau, Hugo" uniqKey="Garneau H" first="Hugo" last="Garneau">Hugo Garneau</name><name sortKey="Gentleman, Beth" sort="Gentleman, Beth" uniqKey="Gentleman B" first="Beth" last="Gentleman">Beth Gentleman</name><name sortKey="Mcelhaney, Janet E" sort="Mcelhaney, Janet E" uniqKey="Mcelhaney J" first="Janet E" last="Mcelhaney">Janet E. Mcelhaney</name><name sortKey="Meneilly, Graydon S" sort="Meneilly, Graydon S" uniqKey="Meneilly G" first="Graydon S" last="Meneilly">Graydon S. Meneilly</name><name sortKey="Tedder, Gale" sort="Tedder, Gale" uniqKey="Tedder G" first="Gale" last="Tedder">Gale Tedder</name></country><country name="Allemagne"><region name="Bade-Wurtemberg"><name sortKey="Pawelec, Graham" sort="Pawelec, Graham" uniqKey="Pawelec G" first="Graham" last="Pawelec">Graham Pawelec</name></region></country><country name="Royaume-Uni"><noRegion><name sortKey="Pawelec, Graham" sort="Pawelec, Graham" uniqKey="Pawelec G" first="Graham" last="Pawelec">Graham Pawelec</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeCanadaV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000117 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000117 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeCanadaV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:27789617
|texte= Cytomegalovirus Seropositivity Predicts a Decline in the T Cell But Not the Antibody Response to Influenza in Vaccinated Older Adults Independent of Type 2 Diabetes Status.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27789617" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeCanadaV4
| This area was generated with Dilib version V0.6.35. |  |